Heilongjiang ZBD Pharmaceutical Co Ltd (603567) Fair Value & Analysis
Healthcare · CN · Market cap 6.6B CNY
Strengths
Risks
Fair value as of: Aug 13, 2026
From 9 valuation models · updated 12 days ago
Share price −4.1% over the past month.
A solid business, but trading 371% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (¥1.95). The favourable scenario is already priced in.
- The model range is unusually wide (¥0.4200 to ¥1.95). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ¥4.28 – ¥18.89 · fair‑value band ¥0.4200 – ¥1.95 · the ¥5.61 price screens above the ¥1.19 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Heilongjiang ZBD Pharmaceutical Co Ltd (603567) currently trades at ¥5.61, while our model-based Fair Value estimate is ¥1.19, implying the stock looks roughly 78.8% overvalued today. The Quality Score stands at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Trailing-twelve-month revenue stands at 510M CNY. Revenue declined 61.3% year over year. It earns a return on equity of -22.4%. Net debt stands at 1.3B CNY. Fundamentals as of Aug 13, 2026
Our scenario range runs from ¥0.4200 (bear case) to ¥1.95 (bull case); at ¥5.61, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 58% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -35% fair-value upside, at -79%, 603567 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 9 models by family
Widest divergence: Asset-Based (¥4.48) versus Multiples (¥2.58). Highest evidence: Growth DCF (80).
Notify me when 603567 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 52 · Market factors (momentum, volatility) 22
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields.
Full company description
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Heilongjiang ZBD Pharmaceutical Co Ltd reported revenue of ¥798M in FY2025 versus ¥4.1B in FY2021, a compound −33.7%/yr. Reported net income was −¥1.4B in FY2025.
of which total revenue +7.9 pp · buybacks/dilution −2.9 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
603567 screens 79% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 634 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.00 | €106.48 | -24% |
| Takeda Pharmaceutical Company TAK | $17.41 | $11.29 | -35% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | -69% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Haleon plc HLN | $9.80 | $7.62 | -22% |
| Teva Pharmaceutical Industries Limited TEVA | $36.74 | $15.37 | -58% |
| Sandoz Group SDZ | CHF 72.64 | CHF 48.68 | -33% |
| Zoetis Inc ZTS | $73.54 | $104.88 | +43% |
| Hansoh Pharmaceutical Group 3692 | HK$33.50 | HK$16.14 | -52% |
Compare Heilongjiang ZBD Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Heilongjiang ZBD Pharmaceutical Co Ltd (603567) overvalued or undervalued?
What is the fair value of 603567?
What is the quality score of 603567?
What is the revenue of Heilongjiang ZBD Pharmaceutical Co Ltd (603567)?
What is the net profit margin of 603567?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Heilongjiang ZBD Pharmaceutical Co Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.